Skip to main content
Erschienen in: Der Gastroenterologe 1/2015

01.01.2015 | Gallenblasen- und Gallengangskarzinom | Schwerpunkt

Kolonkarzinom und Gallengangskarzinom bei primär sklerosierender Cholangitis

verfasst von: Dr. T.J. Weismüller, T.O. Lankisch, T. Voigtländer

Erschienen in: Die Gastroenterologie | Ausgabe 1/2015

Einloggen, um Zugang zu erhalten

Zusammenfassung

Die primär sklerosierende Cholangitis (PSC) ist mit einem deutlich erhöhten Risiko hepatobiliärer und kolorektaler Karzinome assoziiert. Einheitliche Überwachungsprogramme bei Patienten mit PSC zur Detektion kolorektaler Karzinome sowie eines Cholangiokarzinoms (CC) sind bisher nicht etabliert. Neben der Labordiagnostik werden bildgebende und komplexe endoskopische Verfahren in bestimmten Zeitintervallen eingesetzt, um eine frühzeitige CC-Diagnose zu stellen. Bei gleichzeitig bestehender chronisch-entzündlicher Darmerkrankung sind jährliche Vorsorgekoloskopien erforderlich. Die Lebertransplantation als potenziell kuratives Therapieverfahren der PSC muss frühzeitig diskutiert und ständig reevaluiert werden. In dieser Übersichtsarbeit liegt der Schwerpunkt auf risikoadaptierten Überwachungsstrategien für das kolorektale sowie das Cholangiokarzinom.
Literatur
1.
Zurück zum Zitat Alvaro D (2009) Serum and bile biomarkers for cholangiocarcinoma. Curr Opin Gastroenterol 25: 279–284PubMedCrossRef Alvaro D (2009) Serum and bile biomarkers for cholangiocarcinoma. Curr Opin Gastroenterol 25: 279–284PubMedCrossRef
2.
Zurück zum Zitat Bergquist A, Ekbom A, Olsson R et al (2002) Hepatic and extrahepatic malignancies in primary sclerosing cholangitis. J Hepatol 36: 321–327PubMedCrossRef Bergquist A, Ekbom A, Olsson R et al (2002) Hepatic and extrahepatic malignancies in primary sclerosing cholangitis. J Hepatol 36: 321–327PubMedCrossRef
3.
Zurück zum Zitat Boberg KM, Bergquist A, Mitchell S et al (2002) Cholangiocarcinoma in primary sclerosing cholangitis: risk factors and clinical presentation. Scand J Gastroenterol 37: 1205–1211PubMedCrossRef Boberg KM, Bergquist A, Mitchell S et al (2002) Cholangiocarcinoma in primary sclerosing cholangitis: risk factors and clinical presentation. Scand J Gastroenterol 37: 1205–1211PubMedCrossRef
4.
Zurück zum Zitat Boonstra K, Weersma RK, Erpecum KJ van et al (2013) Population-based epidemiology, malignancy risk, and outcome of primary sclerosing cholangitis. Hepatology 58: 2045–2055PubMedCrossRef Boonstra K, Weersma RK, Erpecum KJ van et al (2013) Population-based epidemiology, malignancy risk, and outcome of primary sclerosing cholangitis. Hepatology 58: 2045–2055PubMedCrossRef
5.
Zurück zum Zitat Braden B, Halliday J, Aryasingha S et al (2012) Risk for colorectal neoplasia in patients with colonic Crohn’s disease and concomitant primary sclerosing cholangitis. Clin Gastroenterol Hepatol 10: 303–308PubMedCrossRef Braden B, Halliday J, Aryasingha S et al (2012) Risk for colorectal neoplasia in patients with colonic Crohn’s disease and concomitant primary sclerosing cholangitis. Clin Gastroenterol Hepatol 10: 303–308PubMedCrossRef
6.
Zurück zum Zitat Broome U, Olsson R, Loof L et al (1996) Natural history and prognostic factors in 305 Swedish patients with primary sclerosing cholangitis. Gut 38: 610–615PubMedCentralPubMedCrossRef Broome U, Olsson R, Loof L et al (1996) Natural history and prognostic factors in 305 Swedish patients with primary sclerosing cholangitis. Gut 38: 610–615PubMedCentralPubMedCrossRef
7.
Zurück zum Zitat Dignass A, Preiss JC, Aust DE et al (2011) Updated German guideline on diagnosis and treatment of ulcerative colitis, 2011. Z Gastroenterol 49: 1276–1341PubMedCrossRef Dignass A, Preiss JC, Aust DE et al (2011) Updated German guideline on diagnosis and treatment of ulcerative colitis, 2011. Z Gastroenterol 49: 1276–1341PubMedCrossRef
8.
Zurück zum Zitat Eaton JE, Thackeray EW, Lindor KD (2012) Likelihood of malignancy in gallbladder polyps and outcomes following cholecystectomy in primary sclerosing cholangitis. Am J Gastroenterol 107: 431–439PubMedCrossRef Eaton JE, Thackeray EW, Lindor KD (2012) Likelihood of malignancy in gallbladder polyps and outcomes following cholecystectomy in primary sclerosing cholangitis. Am J Gastroenterol 107: 431–439PubMedCrossRef
9.
Zurück zum Zitat Gizard E, Ford AC, Bronowicki JP et al (2014) Systematic review: the epidemiology of the hepatobiliary manifestations in patients with inflammatory bowel disease. Aliment Pharmacol Ther 40: 3–15PubMedCrossRef Gizard E, Ford AC, Bronowicki JP et al (2014) Systematic review: the epidemiology of the hepatobiliary manifestations in patients with inflammatory bowel disease. Aliment Pharmacol Ther 40: 3–15PubMedCrossRef
10.
Zurück zum Zitat Heinzow HS, Kammerer S, Rammes C et al (2014) Comparative analysis of ERCP, IDUS, EUS and CT in predicting malignant bile duct strictures. World J Gastroenterol 20: 10495–10503PubMedCentralPubMedCrossRef Heinzow HS, Kammerer S, Rammes C et al (2014) Comparative analysis of ERCP, IDUS, EUS and CT in predicting malignant bile duct strictures. World J Gastroenterol 20: 10495–10503PubMedCentralPubMedCrossRef
11.
Zurück zum Zitat Kalaitzakis E, Sturgess R, Kaltsidis H et al (2014) Diagnostic utility of single-user peroral cholangioscopy in sclerosing cholangitis. Scand J Gastroenterol 49: 1237–1244PubMedCrossRef Kalaitzakis E, Sturgess R, Kaltsidis H et al (2014) Diagnostic utility of single-user peroral cholangioscopy in sclerosing cholangitis. Scand J Gastroenterol 49: 1237–1244PubMedCrossRef
12.
Zurück zum Zitat Kim WR, Therneau TM, Wiesner RH et al (2000) A revised natural history model for primary sclerosing cholangitis. Mayo Clin Proc 75: 688–694PubMedCrossRef Kim WR, Therneau TM, Wiesner RH et al (2000) A revised natural history model for primary sclerosing cholangitis. Mayo Clin Proc 75: 688–694PubMedCrossRef
13.
Zurück zum Zitat Lankisch TO, Metzger J, Negm AA et al (2011) Bile proteomic profiles differentiate cholangiocarcinoma from primary sclerosing cholangitis and choledocholithiasis. Hepatology 53: 875–884PubMedCrossRef Lankisch TO, Metzger J, Negm AA et al (2011) Bile proteomic profiles differentiate cholangiocarcinoma from primary sclerosing cholangitis and choledocholithiasis. Hepatology 53: 875–884PubMedCrossRef
14.
Zurück zum Zitat Li C, Wang W, Ding H et al (2013) Value of contrast-enhanced sonography in the diagnosis of peripheral intrahepatic cholangiocarcinoma. J Clin Ultrasound 39: 447–453CrossRef Li C, Wang W, Ding H et al (2013) Value of contrast-enhanced sonography in the diagnosis of peripheral intrahepatic cholangiocarcinoma. J Clin Ultrasound 39: 447–453CrossRef
15.
Zurück zum Zitat Li L, Masica D, Ishida M et al (2014) Human bile contains microRNA-laden extracellular vesicles that can be used for cholangiocarcinoma diagnosis. Hepatology 60: 896–907PubMedCrossRef Li L, Masica D, Ishida M et al (2014) Human bile contains microRNA-laden extracellular vesicles that can be used for cholangiocarcinoma diagnosis. Hepatology 60: 896–907PubMedCrossRef
16.
Zurück zum Zitat Lindkvist B, Benito de Valle M, Gullberg B et al (2010) Incidence and prevalence of primary sclerosing cholangitis in a defined adult population in Sweden. Hepatology 52: 571–577PubMedCrossRef Lindkvist B, Benito de Valle M, Gullberg B et al (2010) Incidence and prevalence of primary sclerosing cholangitis in a defined adult population in Sweden. Hepatology 52: 571–577PubMedCrossRef
17.
Zurück zum Zitat Lindstrom L, Lapidus A, Ost A et al (2011) Increased risk of colorectal cancer and dysplasia in patients with Crohn’s colitis and primary sclerosing cholangitis. Dis Colon Rectum 54: 1392–1397PubMedCrossRef Lindstrom L, Lapidus A, Ost A et al (2011) Increased risk of colorectal cancer and dysplasia in patients with Crohn’s colitis and primary sclerosing cholangitis. Dis Colon Rectum 54: 1392–1397PubMedCrossRef
18.
Zurück zum Zitat Loftus EV Jr, Harewood GC, Loftus CG et al (2005) PSC-IBD: a unique form of inflammatory bowel disease associated with primary sclerosing cholangitis. Gut 54: 91–96PubMedCentralPubMedCrossRef Loftus EV Jr, Harewood GC, Loftus CG et al (2005) PSC-IBD: a unique form of inflammatory bowel disease associated with primary sclerosing cholangitis. Gut 54: 91–96PubMedCentralPubMedCrossRef
19.
Zurück zum Zitat Lundqvist K, Broome U (1997) Differences in colonic disease activity in patients with ulcerative colitis with and without primary sclerosing cholangitis: a case control study. Dis Colon Rectum 40: 451–456PubMedCrossRef Lundqvist K, Broome U (1997) Differences in colonic disease activity in patients with ulcerative colitis with and without primary sclerosing cholangitis: a case control study. Dis Colon Rectum 40: 451–456PubMedCrossRef
20.
Zurück zum Zitat Lutz HH, Wasmuth HE, Streetz K et al (2012) Endoscopic ultrasound as an early diagnostic tool for primary sclerosing cholangitis: a prospective pilot study. Endoscopy 44: 934–939PubMedCrossRef Lutz HH, Wasmuth HE, Streetz K et al (2012) Endoscopic ultrasound as an early diagnostic tool for primary sclerosing cholangitis: a prospective pilot study. Endoscopy 44: 934–939PubMedCrossRef
21.
Zurück zum Zitat Marchesa P, Lashner BA, Lavery IC et al (1997) The risk of cancer and dysplasia among ulcerative colitis patients with primary sclerosing cholangitis. Am J Gastroenterol 92: 1285–1288PubMed Marchesa P, Lashner BA, Lavery IC et al (1997) The risk of cancer and dysplasia among ulcerative colitis patients with primary sclerosing cholangitis. Am J Gastroenterol 92: 1285–1288PubMed
22.
Zurück zum Zitat Metzger J, Negm AA, Plentz RR et al (2013) Urine proteomic analysis differentiates cholangiocarcinoma from primary sclerosing cholangitis and other benign biliary disorders. Gut 62: 122–130PubMedCrossRef Metzger J, Negm AA, Plentz RR et al (2013) Urine proteomic analysis differentiates cholangiocarcinoma from primary sclerosing cholangitis and other benign biliary disorders. Gut 62: 122–130PubMedCrossRef
23.
Zurück zum Zitat Munkholm P (2003) Review article: the incidence and prevalence of colorectal cancer in inflammatory bowel disease. Aliment Pharmacol Ther 18(Suppl 2): 1–5PubMedCrossRef Munkholm P (2003) Review article: the incidence and prevalence of colorectal cancer in inflammatory bowel disease. Aliment Pharmacol Ther 18(Suppl 2): 1–5PubMedCrossRef
24.
Zurück zum Zitat Nehls O, Gregor M, Klump B (2004) Serum and bile markers for cholangiocarcinoma. Semin Liver Dis 24: 139–154PubMedCrossRef Nehls O, Gregor M, Klump B (2004) Serum and bile markers for cholangiocarcinoma. Semin Liver Dis 24: 139–154PubMedCrossRef
25.
Zurück zum Zitat Pardi DS, Loftus EV Jr, Kremers WK et al (2003) Ursodeoxycholic acid as a chemopreventive agent in patients with ulcerative colitis and primary sclerosing cholangitis. Gastroenterology 124: 889–893PubMedCrossRef Pardi DS, Loftus EV Jr, Kremers WK et al (2003) Ursodeoxycholic acid as a chemopreventive agent in patients with ulcerative colitis and primary sclerosing cholangitis. Gastroenterology 124: 889–893PubMedCrossRef
26.
Zurück zum Zitat Rudolph G, Gotthardt D, Kloeters-Plachky P et al (2010) In PSC with dominant bile duct stenosis, IBD is associated with an increase of carcinomas and reduced survival. J Hepatol 53: 313–317PubMedCrossRef Rudolph G, Gotthardt D, Kloeters-Plachky P et al (2010) In PSC with dominant bile duct stenosis, IBD is associated with an increase of carcinomas and reduced survival. J Hepatol 53: 313–317PubMedCrossRef
27.
Zurück zum Zitat Sangfelt P, Sundin A, Wanders A et al (2014) Monitoring dominant strictures in primary sclerosing cholangitis with brush cytology and FDG-PET. J Hepatol Sangfelt P, Sundin A, Wanders A et al (2014) Monitoring dominant strictures in primary sclerosing cholangitis with brush cytology and FDG-PET. J Hepatol
28.
Zurück zum Zitat Shetty K, Rybicki L, Brzezinski A et al (1999) The risk for cancer or dysplasia in ulcerative colitis patients with primary sclerosing cholangitis. Am J Gastroenterol 94: 1643–1649PubMedCrossRef Shetty K, Rybicki L, Brzezinski A et al (1999) The risk for cancer or dysplasia in ulcerative colitis patients with primary sclerosing cholangitis. Am J Gastroenterol 94: 1643–1649PubMedCrossRef
29.
Zurück zum Zitat Singh S, Edakkanambeth Varayil J, Loftus EV Jr et al (2013) Incidence of colorectal cancer after liver transplantation for primary sclerosing cholangitis: a systematic review and meta-analysis. Liver Transpl 19: 1361–1369PubMedCrossRef Singh S, Edakkanambeth Varayil J, Loftus EV Jr et al (2013) Incidence of colorectal cancer after liver transplantation for primary sclerosing cholangitis: a systematic review and meta-analysis. Liver Transpl 19: 1361–1369PubMedCrossRef
30.
Zurück zum Zitat Soetikno RM, Lin OS, Heidenreich PA et al (2002) Increased risk of colorectal neoplasia in patients with primary sclerosing cholangitis and ulcerative colitis: a meta-analysis. Gastrointest Endosc 56: 48–54PubMedCrossRef Soetikno RM, Lin OS, Heidenreich PA et al (2002) Increased risk of colorectal neoplasia in patients with primary sclerosing cholangitis and ulcerative colitis: a meta-analysis. Gastrointest Endosc 56: 48–54PubMedCrossRef
31.
Zurück zum Zitat Stahlberg D, Veress B, Tribukait B et al (2003) Atrophy and neoplastic transformation of the ileal pouch mucosa in patients with ulcerative colitis and primary sclerosing cholangitis: a case control study. Dis Colon Rectum 46: 770–778PubMedCrossRef Stahlberg D, Veress B, Tribukait B et al (2003) Atrophy and neoplastic transformation of the ileal pouch mucosa in patients with ulcerative colitis and primary sclerosing cholangitis: a case control study. Dis Colon Rectum 46: 770–778PubMedCrossRef
32.
Zurück zum Zitat Tischendorf JJ, Meier PN, Strassburg CP et al (2006) Characterization and clinical course of hepatobiliary carcinoma in patients with primary sclerosing cholangitis. Scand J Gastroenterol 41: 1227–1234PubMedCrossRef Tischendorf JJ, Meier PN, Strassburg CP et al (2006) Characterization and clinical course of hepatobiliary carcinoma in patients with primary sclerosing cholangitis. Scand J Gastroenterol 41: 1227–1234PubMedCrossRef
33.
Zurück zum Zitat Trikudanathan G, Navaneethan U, Njei B et al (2014) Diagnostic yield of bile duct brushings for cholangiocarcinoma in primary sclerosing cholangitis: a systematic review and meta-analysis. Gastrointest Endosc 79: 783–789PubMedCrossRef Trikudanathan G, Navaneethan U, Njei B et al (2014) Diagnostic yield of bile duct brushings for cholangiocarcinoma in primary sclerosing cholangitis: a systematic review and meta-analysis. Gastrointest Endosc 79: 783–789PubMedCrossRef
34.
Zurück zum Zitat Tsaitas C, Semertzidou A, Sinakos E (2014) Update on inflammatory bowel disease in patients with primary sclerosing cholangitis. World J Hepatol 6: 178–187PubMedCentralPubMedCrossRef Tsaitas C, Semertzidou A, Sinakos E (2014) Update on inflammatory bowel disease in patients with primary sclerosing cholangitis. World J Hepatol 6: 178–187PubMedCentralPubMedCrossRef
35.
Zurück zum Zitat Velayos FS, Terdiman JP, Walsh JM (2005) Effect of 5-aminosalicylate use on colorectal cancer and dysplasia risk: a systematic review and metaanalysis of observational studies. Am J Gastroenterol 100: 1345–1353PubMedCrossRef Velayos FS, Terdiman JP, Walsh JM (2005) Effect of 5-aminosalicylate use on colorectal cancer and dysplasia risk: a systematic review and metaanalysis of observational studies. Am J Gastroenterol 100: 1345–1353PubMedCrossRef
36.
Zurück zum Zitat Venkatesh PG, Navaneethan U, Shen B et al (2013) Increased serum levels of carbohydrate antigen 19-9 and outcomes in primary sclerosing cholangitis patients without cholangiocarcinoma. Dig Dis Sci 58: 850–857PubMedCrossRef Venkatesh PG, Navaneethan U, Shen B et al (2013) Increased serum levels of carbohydrate antigen 19-9 and outcomes in primary sclerosing cholangitis patients without cholangiocarcinoma. Dig Dis Sci 58: 850–857PubMedCrossRef
37.
Zurück zum Zitat Weismüller T, Strassburg C, Manns M et al (2012) Sklerosierende Cholangitiden. Gastroenterologe 7: 483–492CrossRef Weismüller T, Strassburg C, Manns M et al (2012) Sklerosierende Cholangitiden. Gastroenterologe 7: 483–492CrossRef
38.
Zurück zum Zitat Weismuller TJ, Lankisch TO (2011) Medical and endoscopic therapy of primary sclerosing cholangitis. Best Pract Res Clin Gastroenterol 25: 741–752PubMedCrossRef Weismuller TJ, Lankisch TO (2011) Medical and endoscopic therapy of primary sclerosing cholangitis. Best Pract Res Clin Gastroenterol 25: 741–752PubMedCrossRef
39.
40.
Zurück zum Zitat Zenouzi R, Weismuller TJ, Hubener P et al (2014) Low risk of hepatocellular carcinoma in patients with primary sclerosing cholangitis with cirrhosis. Clin Gastroenterol Hepatol 12: 1733–1738PubMedCrossRef Zenouzi R, Weismuller TJ, Hubener P et al (2014) Low risk of hepatocellular carcinoma in patients with primary sclerosing cholangitis with cirrhosis. Clin Gastroenterol Hepatol 12: 1733–1738PubMedCrossRef
Metadaten
Titel
Kolonkarzinom und Gallengangskarzinom bei primär sklerosierender Cholangitis
verfasst von
Dr. T.J. Weismüller
T.O. Lankisch
T. Voigtländer
Publikationsdatum
01.01.2015
Verlag
Springer Berlin Heidelberg
Erschienen in
Die Gastroenterologie / Ausgabe 1/2015
Print ISSN: 2731-7420
Elektronische ISSN: 2731-7439
DOI
https://doi.org/10.1007/s11377-014-0941-0

Weitere Artikel der Ausgabe 1/2015

Der Gastroenterologe 1/2015 Zur Ausgabe

Mitteilungen des BDI

Mitteilungen des BDI

Mitteilungen der Stiftung LebensBlicke

Mitteilungen der Stiftung LebensBlicke

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.